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disease in a screened cohort.
Background. Obesity is associated with proteinuria and could
be a risk factor for end-stage renal disease (ESRD). However,
few studies have examined the significance of body mass index
(BMI) as a risk factor for the development of ESRD in the
general population.
Methods. We examined the relationship between BMI and
the development of ESRD using data from a 1983 community-
based screening in Okinawa, Japan. Screenees who developed
ESRD by the end of 2000 were identified through the Okinawa
Dialysis Study registry. BMI data were available for 100,753
screenees (47,504 men and 53,249 women) aged ≥20 years. The
cumulative incidence of ESRD was analyzed according to the
quartile of BMI: <21.0, 21.0 to 23.1, 23.2 to 25.4, and ≥25.5
kg/m2.
Results. The mean (SD) BMI of the screenees was 23.4 (3.3)
kg/m2 (range 7.9 to 59.1 kg/m2); the mean was 23.4 kg/m2 for
both men and women. During the follow-up period, 404 scree-
nees (232 men and 172 women) developed ESRD. The cumu-
lative incidences of ESRD per 1000 screenees were, from the
lowest to highest BMI quartile, 2.48, 3.79, 3.86, and 5.81. The
odds ratio (95% CI) of BMI for developing ESRD, after adjust-
ment for age, sex, systolic blood pressure, and proteinuria, was
1.273 (1.121–1.446, P = 0.0002) for men and 0.950 (0.825–1.094,
not significant) for women.
Conclusion. We found that BMI was associated with an in-
creased risk of the development of ESRD in men in the gen-
eral population in Okinawa. The maintenance of optimal body
weight may reduce the risk of ESRD.
The number of patients with end-stage renal disease
(ESRD) requiring chronic dialysis therapy is increasing
worldwide [1–3]. The early detection and treatment of
individuals at high risk may reduce the burden of ESRD.
The relationships of excess body weight with all-cause
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and cardiovascular mortality are well established [4–7].
However, only a few studies have examined the influence
of being overweight or obese on the risk of developing
ESRD. Proteinuria has been found to be among the most
powerful predictors of ESRD in mass screening settings
[8, 9]. The relationship between body mass index (BMI)
and proteinuria is therefore interesting. In a large cross-
sectional population study, Ramirez et al [10] found a
J-shaped relationship between BMI and the prevalence
of proteinuria. We previously observed that BMI was an
independent predictor of the development of proteinuria
in men [11]. Donor-recipient body size mismatch is an
important predictor of disease progression [12] and graft
loss in renal transplantation; being overweight or obese
could therefore be a significant risk factor for ESRD. Our
preliminary report suggested that BMI was not a major
risk factor for the development of ESRD [13]; however,
the 10-year follow-up period may have been insufficient
to establish any relationship between these factors. We
have extended this follow-up period to 17 years; here we
report our findings on the relationship between BMI and
the risk of developing ESRD.
METHODS
Study design
All subjects over age 20 years who participated in the
1983 mass health screening examinations in Okinawa,
Japan, were eligible for the study. Okinawa consists of
a number of subtropical islands in the southernmost part
of Japan. The population in 1983 was approximately 1.14
million. Screening participants were excluded from the
present study if their date of birth, height, or weight were
not available in the registry files. In a subgroup of the
screenees data for fasting blood glucose were available.
Dialysis patients who were among the 1983 screening
participants, and individuals who became dialysis pa-
tients between 1983 and December 2000, were identi-
fied from the Okinawa Dialysis Study (OKIDS) registry.
The OKDIS registry includes information on all dialysis
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patients in the Okinawa area. The identity of dialysis pa-
tients was verified through the review of medical charts
in the dialysis units. The cumulative incidence of ESRD
and the odds ratio (OR) for developing ESRD according
to the quartile of BMI at screening were calculated. The
institutional ethics committee approved the protocol for
this study.
Mass screening
The Okinawa General Health Maintenance Associ-
ation (OGHMA), a nonprofit agency directed by Dr.
Y. Ikemiya, performs a large community-based health
examination annually [8]. OGHMA staff, doctors, and
nurses visit sites accessible to Okinawa residents and day-
time employees, who participate in the screening vol-
untarily. Screenees are interviewed and given physical
examinations, a urine test, and blood tests. They are in-
formed of the results of these tests and advised when to
seek further care. During the screening, blood pressure is
measured by clinical staff with a standard mercury sphyg-
momanometer with the screenee seated. The urine test
consists of dipstick urinalysis (Ames dipstick) for pro-
teinuria and is performed on spontaneously voided fresh
urine. The urine test results are interpreted by OGHMA
physicians or their assistants and are recorded as “−,”
“+/−,” “1+,” “2+,” “3+,” or “4+.” Results recorded as
“−” or “+/−” are defined as normal; others are defined as
abnormal. BMI was calculated as the weight in kg divided
by the square of the height in meters. Diabetes mellitus
(DM) was diagnosed when the fasting blood glucose was
≥126 mg/dL. The computer-based screening data used
in this study included information acquired from April 1,
1983, through to March 31, 1984. The present analysis was
conducted on 100,753 screenees (47,504 men and 53,249
women), or about 13.0% of the total adult Okinawa pop-
ulation in 1983. Screenees who were already on chronic
dialysis at the time of the screening were excluded from
the study.
Dialysis registry in Okinawa
By the end of 2000, there were 46 dialysis units in Ok-
inawa: 9 in the public sector, 17 in private hospitals, and
20 in clinics. All chronic dialysis patients residing in Oki-
nawa who survive at least 1 month on scheduled dialysis
are included in the OKIDS registry [14]. Patients dying
within 1 month of the start of dialysis are not included
in the registry because it is unknown whether their re-
nal function is improving and if other medical conditions
account for their rapid demise. Pertinent clinical informa-
tion for the new dialysis patients, and medical events in
the existing dialysis patients, was collected by the collab-
orating physicians acknowledged below. Records were
updated at least twice a year for medical events, in-
cluding death, renal transplantation, and patient trans-
fer out of Okinawa. If necessary, other information was
obtained through nurses, medical clerks, and the patients
themselves. All patients were followed-up until a major
medical event, or until December, 2000, whichever oc-
curred first, and all outcomes were verified. The number
of ESRD transferred outside was only 1.2% during the
past 30 years [14].
Criteria for the determination of the cause of ESRD
were neither simple nor standardized. Therefore, med-
ical records were further reviewed, and patients were
grouped according to one of six disease categories [14]:
chronic glomerulonephritis, diagnosed when proteinuria
and/or hematuria was noted before the onset of hyperten-
sion and renal failure; nephrosclerosis, diagnosed when
hypertension or major vascular disease was documented
before the onset of renal failure; diabetes mellitus (DM)
nephropathy, diagnosed by a long history of DM, the pres-
ence of DM retinopathy, and the use of insulin; systemic
lupus erythematosus, diagnosed according to the Ameri-
can Rheumatism Association criteria; and polycystic kid-
ney disease, diagnosed after chart review by the presence
of multiple cysts and a family history of the disease.
The sixth category—“other disease”—included patients
who did not fall into one of the aforementioned disease
categories.
Statistical analysis
Data are expressed as mean (SD). The unpaired t test or
chi-square test was used to analyze differences in values
or ratios between groups. Trends were estimated by multi-
variate analysis of variance. Multivariate logistic analysis
was used to examine the relationship between BMI and
the development of ESRD after adjustment for age, sex,
systolic blood pressure, and proteinuria. Furthermore, we
performed a similar analysis in a subgroup of the scree-
nees who had data for fasting blood glucose. All analyses
were carried out with SAS (Version 6; SAS Institute, Inc.,
Cary, NC, USA). A result of P < 0.05 was considered sta-
tistically significant.
RESULTS
For both men and women, BMI was normally dis-
tributed (Fig. 1). BMI did not change significantly with
age. For screenees above age 51, BMI was higher for
women than men. The baseline clinical characteristics of
the screened subjects are summarized in Table 1. The
mean (SD) BMI was 23.4 (3.3) kg/m2. BMI was cate-
gorized into quartiles with the following cutoff points:
<21.0, 21.0 to 23.1, 23.2 to 25.4, and ≥25.5 kg/m2.
Age, systolic and diastolic blood pressure, and protein-
uria increased from the lowest to highest BMI quartile
(Table 2).
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Fig. 1. Distribution of body mass index in
men and women at the time of screening.
Screening was completed between April 1,
1983, and March 31, 1984.
Table 1. Baseline clinical characteristics of screened subjects for who
body mass index (BMI) data were available (N = 100,753)
Men (%) 47,504 (47.1%)
Age at screening years 49.6 (16.2)
Height cm 154.1 (9.1)
Weight kg 55.9 (10.3)
Body mass index kg/m2 23.4 (3.3)
Systolic blood pressure mm Hg 130.3 (19.4)
Diastolic blood pressure mm Hg 78.7 (11.4)
Proteinuria 5291 (5.3%)
Data are expressed as mean (SD). Screening was performed in Okinawa, Japan,
from April 1, 1983, to March 31, 1984. Data for blood pressure and proteinuria
were available for more than 98% of screenees. Proteinuria denotes dipstick
positive (≥1+).
Table 2. Baseline clinical characteristics of the screenees by the
quartiles of body mass index
BMIkg/m2
<21.0 21.0–23.1 23.2–25.4 ≥25.5
N 24,155 25,826 25,130 25,642
Mean BMI 19.4 (1.2) 22.1 (0.6) 24.2 (0.7) 27.8 (2.2)
Men % 44.8% 48.3% 50.0% 45.4%
Age at screening 48.7 (19.3) 49.1 (16.6) 50.1 (14.9) 50.3 (13.6)
years
SBP mm Hg 123.6 (18.8) 128.0 (18.7) 131.9 (18.6) 137.2 (19.1)
DBP mm Hg 73.8 (10.5) 76.9 (10.5) 79.9 (10.6) 84.0 (11.2)
Proteinuria % 4.5% 4.5% 4.9% 7.5%
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure.
Data are expressed as mean (SD). Trends were all significant, P < 0.0001, by
quartile of BMI.
During the follow-up period, 404 screenees (232 men
and 172 women) required scheduled dialysis. Baseline
data for these screenees is summarized in Table 3. The
mean (SD) BMI for these subjects was 24.4 (3.4) kg/m2.
At the time of start of dialysis, it was 22.3 (3.0) kg/m2, P <
0.0001 by paired t test. The 17-year cumulative incidence
of ESRD by BMI quartile is shown in Figure 2. The mean
Table 3. Baseline clinical characteristics of the screenees who
developed end-stage renal disease (ESRD) during the study period
(N = 404)
Men (%) 232 (57.4%)
Age at screening years 53.1 (13.0)
Height cm 154.4 (8.5)
Weight kg 58.6 (10.6)
Body mass index kg/m2 24.4 (3.4)
Systolic blood pressure mm Hg 144.2 (22.1)
Diastolic blood pressure mm Hg 86.7 (12.8)
Proteinuria % 44.8 %
Cause of ESRD
Chronic glomerulonephritis 198 (49.0%)
Diabetes mellitus 98 (24.3%)
Polycystic kidney disease 10 (2.5%)
Systemic lupus erythematosus 6 (1.5%)
Nephrosclerosis 51 (12.6%)
Other 41 (10.1%)
Data are expressed as mean (SD).
time from the screening to the start of dialysis was 109.6
months in those with BMI <21.0 kg/m2, 122.2 months
in those with BMI 21.0 to 23.1 kg/m2, 132.2 months in
those with BMI 23.2 to 25.4 kg/m2, and 139.2 months in
those with BMI ≥25.5 kg/m2. Twelve out of 404 screenees
(2.97%) entered ESRD program within 24 months after
screening. Their mean (SD) BMI was 23.6 (2.6) kg/m2,
which was slightly lower than the mean (SD) of screenees
who entered ESRD 24 months later of 24.5 (3.4) kg/m2
(N = 392, not significant).
The contribution of BMI to the risk of developing
ESRD was evaluated by multivariate logistic analysis.
The adjusted odds ratio (95% CI) was 1.111 (1.012–1.220,
P = 0.0274) for BMI categorized into quartiles (Table 4).
Quartile BMI was a significant predictor of ESRD in men,
for whom the adjusted odds ratio was 1.273 (1.121–1.446,
P = 0.0002). However, this was not true for women, for
whom the adjusted odds ratio was 0.950 (0.825–1.094,
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Fig. 2. Cumulative incidence of end-stage re-
nal disease according to quartile of body mass
index at the time of screening.
not significant). When BMI was considered as a con-
tinuous variable, the adjusted odds ratio for men was
1.063 (1.023–1.104, P = 0.0020), and for women was 0.988
(0.948–1.031, not significant).
Similar results were obtained even after excluding the
screenees with BMI <15 kg/m2 (N = 78). Because the
impact of the presence of proteinuria is strong, we reeval-
uated the contribution of BMI in both the screened sub-
jects with proteinuria and those without proteinuria at
the baseline. In the screenees with proteinuria, the OR
(95% CI) of BMI was 1.020 (0.851–1.222, not signifi-
cant) for men and 0.945 (0.764–1.170, not significant) for
women. However, in the screenees without proteinuria,
the OR (95% CI) of BMI was 1.516 (1.270–1.809, P <
0.0001) for men and 0.940 (0.780–1.132, not significant)
for women. In a subgroup of the screened cohort (N =
14,094, 14% of the total), the prevalence of DM was 5.4%
(N = 761). The prevalence of DM was 4.0% in the scree-
nees with BMI <21.0 kg/m2, 4.8% in those with BMI 21.0
to 23.1 kg/m2, 5.0% in those with BMI 23.2 to 25.4 kg/
m2, and 7.3% in those BMI 25.5 kg/m2. The mean
BMI was significantly higher in the screenees with DM
(24.7 kg/m2) than that of non-DM screenees (23.8 kg/m2,
P < 0.0001). Significance of BMI on the risk of devel-
oping ESRD was lost in men (N = 7323) after including
the presence of DM in addition to variables in Table 4
(the adjusted OR 0.988, 95% CI 0.735–1.327). Even in
non-DM screenees (N = 6943), the significance of BMI
was not clear (the adjusted OR of 0.933, 95% CI 0.697–
1.250).
The adjusted odds ratio for men in the highest
compared with the lowest quartile of BMI was 2.389
(1.529–3.735, P = 0.0001) and for women was 0.8430
(0.604–1.510, not significant) (Table 5).
DISCUSSION
Obesity is known to have a negative impact on renal
disease, and it is closely associated with hypertension,
hyperlipidemia, and microalbuminuria [15, 16]. A signifi-
cant correlation between obesity and urinary albumin ex-
cretion has been reported in a large cross-sectional study
of middle-aged men and women [17]. Weight loss and a
decrease in proteinuria have also been found to be sig-
nificantly correlated [18]. The contribution of obesity to
the risk of ESRD has not been adequately studied in a
large population. Our data suggest that the maintenance
of an optimal body weight may reduce the risk of ESRD,
independent of the effect of blood pressure [19] and pro-
teinuria [8].
The mean BMI of the general population in the United
States is 26.3 kg/m2 [20]; we found that the correspond-
ing figure in Okinawa was 23.4 kg/m2. Our results show
that the prevalence of obesity, defined as BMI 30.0 kg/m2,
in Okinawa was 3.5% in 1983 and 4.8% in 1993; this is
slightly lower than the prevalence of 5.7% in Singapore
[10]. Okinawa was under U.S. control from the end of
World War II until 1972. Since the return to Japanese con-
trol, the lifestyle on the islands has changed, because Oki-
nawa has become more a part of the industrialized world.
Individuals now do less walking and are more likely to
become overweight [21].
There are several plausible mechanisms for the associ-
ation between BMI and ESRD. High BMI is a risk factor
for hypertension, DM, and hyperlipidemia, all of which
increase the risk of ESRD. The number of glomeruli is
dependent on birth weight, and does not increase after
birth. Patients with hypertension [22] or low birth weight
have been observed to have a low number of nephrons.
The incidence of low birth weight (defined as weight less
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Table 4. Results of univariate and multivariate logistic analyses for the development of end-stage renal disease
Univariate Multivariate
Variable OR (95% CI) P value OR (95% CI) P value
Men and women
Age 1.013 (1.007–1.020) <0.0001 1.000 (0.993–1.007) NS
Sex vs. women 1.514 (1.243–1.845) <0.0001 1.510 (1.225–1.861) 0.0001
SBP mm Hg 1.029 (1.025–1.033) <0.0001 1.018 (1.013–1.023) <0.0001
BMIa 1.293 (1.181–1.415) <0.0001 1.111 (1.012–1.220) 0.0274
Proteinuria 3.073 (2.868–3.294) <0.0001 2.835 (2.637–3.048) <0.0001
Men
Age 1.016 (1.008–1.024) <0.0001 1.006 (0.997–1.015) NS
SBP mm Hg 1.030 (1.024–1.035) <0.0001 1.018 (1.011–1.024) <0.0001
BMIa 1.383 (1.222–1.564) <0.0001 1.273 (1.121–1.446) 0.0002
Proteinuria 3.075 (2.804–3.373) <0.0001 2.858 (2.598–3.145) <0.0001
Women
Age 1.016 (1.006–1.025) 0.0012 0.995 (0.984–1.006) NS
SBP mm Hg 1.029 (1.023–1.035) <0.0001 1.019 (1.012–1.027) <0.0001
BMIa 1.192 (1.042–1.364) 0.0103 0.950 (0.825–1.094) NS
Proteinuria 3.064 (2.757–3.404) <0.0001 2.825 (2.528–3.158) <0.0001
NS, not significant; SBP, systolic blood pressure. Proteinuria was categorized as: “−,” “+/−,” “1+,” “2+,” “3+,” or “4+” by dipstick test. Multivariate analyses were
done after including variables such as age, gender, SBP, and proteinuria.
aBMI, body mass index, in quartiles: <21.0, 21.0–23.1, 23.2–25.4, and ≥ 25.5 kg/m2.
Table 5. Adjusted odds ratio (95% CI) for developing ESRD by
BMI quartile
BMI kg/m2 Adjusted odds ratio 95% CI P value
Men and women
<21.0 1
21.0–23.1 1.486 1.070–2.062 0.0181
23.2–25.4 1.338 0.960–1.864 0.0854
≥25.5 1.483 1.083–2.031 0.0140
Men
<21.0 1
21.0–23.1 1.788 1.123–2.846 0.0142
23.2–25.4 1.950 1.230–3.090 0.0045
≥25.5 2.389 1.529–3.735 0.0001
Women
<21.0 1
21.0–23.1 1.249 0.780–1.996 0.3536
23.2–25.4 0.879 0.535–1.445 0.6118
≥25.5 0.955 0.604–1.510 0.8430
Adjusted for age, systolic blood pressure, and proteinuria.
than 2500 g) in Okinawa is 7.4% to 9.3%, and is higher
than the national average of 5.7% [14]. Low birth weight
has been linked to the subsequent development of hy-
pertension and renal failure [23]. This would be more ev-
ident in Okinawa because the prevalence of obesity has
increased recently. Actually, the incidence of ESRD is
highest in Okinawa among Japanese [24]. Interestingly,
although the number of glomeruli is different for each
individual, the average number of glomeruli per person
does not differ by gender [25].
Gender differences in the progression of various re-
nal diseases have been reported. Men are at higher risk
of developing ESRD, and tend to develop ESRD earlier
in life, than women [26–28]. This may in part be caused
by the influence testosterone and other sex hormones
have on gender differences in the risk of proteinuria and
glomerular sclerosis [29]. In addition, differences in the
risk conferred by being overweight or obese may be im-
portant to the gender differences in ESRD risk.
Recently, we showed that smoking and obesity were
significant predictors of proteinuria and, therefore, the
development of ESRD [11]. In Okinawa, the prevalence
of smoking is 43.0% in men and 4.5% in women [11]. It
is likely that smoking alters the effect of BMI on the risk
of death from many diseases, including smoking-related
cancers. Smoking has been reported to be associated with
microalbuminuria independently of blood pressure in a
cross-sectional study of the general population [30] and
in DM patients [31, 32]. Furthermore, Orth et al [33]
showed that smoking increased the risk of ESRD in men
diagnosed with IgA nephropathy or autosomal-dominant
polycystic kidney disease.
In our study, as BMI decreased, the incidence of ESRD
also decreased. However, this does not necessarily im-
ply that low BMI confers a low risk of ESRD. In fact,
Ramirez et al [10] reported that their graph of protein-
uria versus BMI was J-shaped, so that patients at a very
low BMI had an increased risk of proteinuria. How-
ever, they showed racial difference in the relationship
between BMI and proteinuria. Factors related to these
racial differences need to be determined. Our study has
several limitations. First, although all new ESRD pa-
tients were accounted for, subjects who died were not;
deceased patients, therefore, were not excluded from the
logistic analysis. Given the increased morbidity and mor-
tality of obese patients, our data might underestimate
the true importance of BMI to the risk of ESRD. In the
1980s, the incidence of DM in ESRD was low, as in other
parts of Japan [1]. The annual incidence increased from
35.0 per million populations in 1990 to 99.1 per million
populations in 2002 in Japan. Such trends may be ex-
plained by increasing prevalence of DM associated with
obesity in the general population in Japan. The accep-
tance policy for ESRD has been quite open since 1972 in
Japan.
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Second, BMI was measured on only one occasion. We
therefore cannot determine the effects of weight loss or
gain in this study. Body weight may be related to current
health status or health practices. For example, smoking
or chronic disease may lead to weight loss. In patients
with chronic kidney disease, the absorption of dietary
protein and energy, and serum and anthropometric mea-
sures of protein-energy nutritional status progressively
decline with the glomerular filtration rate (GFR) [34, 35].
A higher GFR has been associated with a higher BMI in
men, but not in women [35]. Unfortunately, in our study,
data on serum creatinine was available in only 13.7% of
the screened subjects [36].
Third, subjects who chose to participate in the screen-
ing were generally healthy individuals who were in-
terested in their health. Individuals who were already
diagnosed with renal failure or cancer may have been
less likely to participate in the screening.
Fourth, the incidences of primary renal diseases in the
screened ESRD patients were slightly different than in
the entire ESRD Okinawa population during the study
period. ESRD was caused by DM in 24.3% of screened
ESRD patients but 33.7% of ESRD patients in the gen-
eral Okinawa population during this study period.
Fifth, our database did not include information on
other risk factors related to ESRD risk, including hema-
tocrit, hyperlipidemia, DM, and smoking. In particular,
the relationship between overweight and obesity on the
risk of developing proteinuria [11] and DM should be
examined further in larger population. Low income and
education, potential risk factors for the development of
chronic kidney disease [35, 36], were also not measured
in this study. Finally, regional variations in the prevalence
of obesity and the incidence of ESRD are being identified
with increasing frequency; therefore, our results should
be confirmed in other regions or countries.
CONCLUSION
We found that increasing BMI was associated with an
increased risk of the development of ESRD in men even
after adjustment for blood pressure and proteinuria. The
prevention and treatment of obesity, at least in men, is an
important strategy for reducing the burden of ESRD.
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